Asset Details
Do you wish to reserve the book?
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
Do you wish to request the book?
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
2024
Overview
Purpose
[
177
Lu]Lu-DOTATATE is an established somatostatin receptor (SSTR) agonist for the treatment of metastasized neuroendocrine neoplasms, while the SSTR antagonist [
177
Lu]Lu-DOTA-LM3 has only scarcely been employed in clinics. Impressive preclinical data obtained with [
161
Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of
161
Tb- and
177
Lu-based DOTA-LM3 and DOTATATE in immunocompetent mice.
Methods
Dosimetry calculations were performed based on biodistribution data of the radiopeptides in immunocompetent mice. Treatment-related effects on blood cell counts were assessed on Days 10, 28 and 56 after application of [
161
Tb]Tb-DOTA-LM3 or [
161
Tb]Tb-DOTATATE at 20 MBq per mouse. These radiopeptides were also applied at 100 MBq per mouse and the effects compared to those observed after application of the
177
Lu-labeled counterparts. Bone marrow smears, blood plasma parameters and organ histology were assessed at the end of the study.
Results
The absorbed organ dose was commonly higher for the SSTR antagonist than for the SSTR agonist and for terbium-161 over lutetium-177. Application of a therapeutic activity level of 20 MBq [
161
Tb]Tb-DOTA-LM3 or [
161
Tb]Tb-DOTATATE was well tolerated without major hematological changes. The injection of 100 MBq of the
161
Tb- and
177
Lu-based somatostatin analogues affected the blood cell counts, however. The lymphocytes were 40–50% lower in treated mice compared to the untreated controls on Day 10 irrespective of the radionuclide employed. At the same timepoint, thrombocyte and erythrocyte counts were 30–50% and 6–12% lower, respectively, after administration of the SSTR antagonist (
p
< 0.05) while changes were less pronounced in mice injected with the SSTR agonist. All blood cell counts were in the normal range on Day 56. Histological analyses revealed minimal abnormalities in the kidneys, liver and spleen of treated mice. No correlation was observed between the organ dose and frequency of the occurrence of abnormalities.
Conclusion
Hematologic changes were more pronounced in mice treated with the SSTR antagonist than in those treated with the SSTR agonist. Despite the increased absorbed dose delivered by terbium-161 over lutetium-177, [
161
Tb]Tb-DOTA-LM3 and [
161
Tb]Tb-DOTATATE should be safe at activity levels that are recommended for their respective
177
Lu-based analogues.
Graphical Abstract
